Senesco to present preclinical data of SNS-01 at ASGCT Annual Meeting

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that preclinical data for the Company's lead drug candidate, SNS-01, will be presented on May 20, 2010 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. from May 17 to 22.

The ASGCT Poster Session will be on Thursday May 20 from 6:15 p.m. to 8:15 p.m. Eastern time, and poster presenters will be available during that time. The following poster highlighting Senesco's preclinical data for SNS-01 will be presented:

• Development and Preclinical Testing of Large Batches of SNS01 - an EIF5A-Based Gene Therapy Nanoparticle Designed for the Treatment of Multiple Myeloma Presented by Catherine Taylor, Department of Biology, University of Waterloo, Waterloo, Ontario, Canada, and Richard Dondero, Vice President of Research and Development, Senesco Technologies, Inc., New Brunswick, New Jersey, in Exhibit Hall C & B South, Poster Number #218.

"This study demonstrates that we have resolved earlier scale-up constraints and now have the ability to produce larger volumes of therapeutic. This accomplishment is of particular importance as it gives us confidence that we can produce and preserve ample quantity of drug for our planned Phase I human clinical trial in multiple myeloma," commented Mr. Dondero.

SOURCE Senesco Technologies, Inc.